The indirect cost per capita was $1670 in non-squamous carcinoma pathological type, $1709 in metastatic clinical stage, $2404 in disease progression, $2080 in immunotherapy, and $1491 in the subgroup with no EGFR mutation and ALK rearrangement. The gene discussed is ALK; the disease is squamous cell carcinoma.